NEW YORK, March 6, 2024 /PRNewswire/ — OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the first patient has been dosed in the Phase 1 study evaluating CUSP06 for the treatment of platinum-refractory/resistant ovarian cancer and other advanced solid tumors.